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What\'s new?Real‐world evidence on the attributable costs of diabetes is calculated from individual register data and categorized according to complication progression.The study shows evidence of twofold higher healthcare resource usage in patients with diabetes compared with the diabetes‐free population.The societal diabetes‐attributable costs of diabetes in Denmark 2011 were estimated to be ˜ 4.27 billion EUR, corresponding to 14,349 EUR per patient year.Nearly 60% of diabetes‐attributable costs were ascribed to the 25% of patients with major complications.Steep gradients of increasing costs with increasing complications were evidenced across all cost components.

Introduction {#dme12965-sec-0006}
============

Globally, healthcare systems are facing the challenge of an exponential increase in the prevalence of chronic diseases [1](#dme12965-bib-0001){ref-type="ref"}. This puts a heavy economic burden on society as new successful but costly treatments lead to an increase in care for more people as life expectancy increases.

With \~ 371 million people diagnosed globally [2](#dme12965-bib-0002){ref-type="ref"} and evidence of rapidly increasing prevalence [3](#dme12965-bib-0003){ref-type="ref"}, [4](#dme12965-bib-0004){ref-type="ref"}, [5](#dme12965-bib-0005){ref-type="ref"}, [6](#dme12965-bib-0006){ref-type="ref"}, diabetes mellitus is one of the most burdensome chronic diseases. Diabetes is associated with shorter lifetime, reduced quality of life and economic burdens on the patient and society as a result of healthcare, pharmaceutical drugs, nursing, reduced labour market participation and premature mortality [1](#dme12965-bib-0001){ref-type="ref"}, [7](#dme12965-bib-0007){ref-type="ref"}, [8](#dme12965-bib-0008){ref-type="ref"}, [9](#dme12965-bib-0009){ref-type="ref"}, [10](#dme12965-bib-0010){ref-type="ref"}.

We aimed to present new evidence of the relationship between costs of patients with diabetes, with and without complications, compared with the diabetes‐free population based on data from all relevant national registers in Denmark [11](#dme12965-bib-0011){ref-type="ref"}. Categorizing patients according to their complication progression into no complications, minor complications and major complications, is a novel method intended to inform decision‐makers of a complex problem in an intuitive and easily interpretable way. Our results provide an economic rationale for secondary prevention, which is important to recognize with increasing numbers of patients with the chronic condition of diabetes. Furthermore, the results may contribute to an awareness among decision‐makers regarding the allocation of budgets which can impede shifts of resources between sectors.

Subjects and methods {#dme12965-sec-0007}
====================

Study population {#dme12965-sec-0008}
----------------

Denmark offers unique opportunities for register‐based research in epidemiology and healthcare [11](#dme12965-bib-0011){ref-type="ref"}. The present study is part of a large‐scale register‐based observational investigation, the Diabetes Impact Study 2013, investigating the epidemiological, health economic and socio‐economic aspects of diabetes in Denmark.

The study population was identified from the Danish National Diabetes Register, adjusted for shortcomings [12](#dme12965-bib-0012){ref-type="ref"}, resulting in a period prevalence of *n* = 318,729. Person‐time was quantified as number of person‐years, defined as 365 person‐days (*n* = 297,378). Patient data were combined with data from the Danish National Patient Register [13](#dme12965-bib-0013){ref-type="ref"}, the Danish National Prescription Registry [14](#dme12965-bib-0014){ref-type="ref"}, the Danish National Health Service Register [15](#dme12965-bib-0015){ref-type="ref"}, the Danish Civil Registration System [16](#dme12965-bib-0016){ref-type="ref"} and registers at Statistics Denmark. Municipal statements were used where register data were not available. Data were linked between registers using the unique Danish Personal Identification Number, assigned to each Danish citizen [16](#dme12965-bib-0016){ref-type="ref"}.

Analysis {#dme12965-sec-0009}
--------

Person‐time was stratified by gender and current age (in 5‐year age intervals) into three complication status groups: no complications, minor complications and major complications. Documentation on diagnoses and procedural codes across complication status groups can be found in Table S1.

The cost of illness framework was applied with a societal cost perspective, including both direct and indirect costs, but excluding intangible costs such as psychosocial effects [10](#dme12965-bib-0010){ref-type="ref"}, [17](#dme12965-bib-0017){ref-type="ref"}. The analytical time window was the calendar year, 2011. Costs (market values excluding value added tax) [17](#dme12965-bib-0017){ref-type="ref"}) were defined as opportunity costs valued as alternative forgone use. The following cost components were evaluated on an individual person level from national register data: 1) healthcare services in primary and secondary care including ambulant treatment and emergency room visits; 2) nursing services in own home/assisted facilities and nurse home visits; 3) pharmaceutical drug consumption; and 4) lost productivity including lower annual income, absenteeism and premature mortality, calculated using the human capital approach [17](#dme12965-bib-0017){ref-type="ref"}. Additional cost components (prevention, education, psychological assistance, use of self‐monitoring of blood glucose appliances, insulin pumps, medical appliances, patients' (and informal care givers') own time and depreciation of capital) were conservatively estimated from Statistics Denmark data and the literature. The measurement of cost components is shown in Table S2.

Attributable costs measure the excess costs of patients with diabetes' total healthcare consumption compared with the annual resource consumption of the diabetes‐free population, stratified according to gender and age. This approach means that our attributable cost estimates reflect the cost of care of patients with diabetes including issues not directly associated with diabetes, and not solely the cost of diabetes care. This was applied because earlier studies document that adding up diabetes‐specific diagnoses/services underestimates the attributable costs compared with a case--control method [18](#dme12965-bib-0018){ref-type="ref"}, [19](#dme12965-bib-0019){ref-type="ref"}.

For healthcare services, patients with diabetes were compared with the diabetes‐free population (*n* = 5,261,714 in 2011) stratified by gender and 5‐year age groups. For pharmaceutical drugs, nursing and the labour market, comparisons were made between patients with diabetes and a matched cohort of the diabetes‐free population, consisting of five control subjects per patient with diabetes, matched by age, gender and residence at date of diagnosis (*n* = 1,462,872). As a result of data limitations from source registers, some cost components were calculated per person (pharmaceutical drugs, nursing, productivity loss) and some per person‐years (healthcare costs). In calculations across the different sectors, person‐years were applied.

Direct associations between cost components and complication status groups were explored in a multivariate linear regression analysis, controlling for potential confounders (gender, age, highest attained education level, ethnicity, year of death and region of residence). The dependent variables were: total and attributable healthcare cost (EUR per person‐years) in primary and secondary care; total net pharmaceutical drug costs; and total costs for home nursing (EUR per year) in 2011, defined per group according to the independent variables. The definitions of these variables are given in Table S3. T‐tests were performed and the significance valued at the 1% level.

Costs were further analysed according to first ascertainment source in the Danish National Diabetes Register as we have previously seen that up to 20% of registrants in the Danish National Diabetes Register are included only as a result of frequent blood glucose measurements and may not have diabetes [12](#dme12965-bib-0012){ref-type="ref"}.

Results {#dme12965-sec-0010}
=======

Estimates for total and attributable costs and costs per person‐year across cost components, gender and complication status groups are shown in Tables [1](#dme12965-tbl-0001){ref-type="table-wrap"}, [2](#dme12965-tbl-0002){ref-type="table-wrap"}, [3](#dme12965-tbl-0003){ref-type="table-wrap"}. Estimates excluding possible 'false‐positive' patients are shown in Tables S4 and S5. All cost estimates are presented in Euro (EUR).

###### 

Total diabetes resource use (total costs) and costs per person‐year for the entire diabetes population according to complication status and gender

  Cost item                                                                   Total costs (EUR)   Total cost per person‐years (EUR)                                                              
  --------------------------------------------------------------------------- ------------------- ----------------------------------- --------------- --------------- -------- -------- -------- --------
  **Healthcare costs**                                                        1,638,237,935       553,933,413                         319,439,149     764,865,373     5,509    3,361    5,508    10,257
  Women                                                                       741,592,485         302,682,783                         139,460,753     299,448,949     5,140    3,445    5,670    9,409
  Men                                                                         896,645,450         251,250,630                         179,978,396     465,416,424     5,857    3,265    5,388    10,889
  **Primary care**                                                            221,176,905         110,599,788                         42,068,988      68,508,128      744      671      725      919
  Women                                                                       113,618,643         63,234,638                          19,779,391      30,604,615      787      720      804      962
  Men                                                                         107,558,262         47,365,151                          22,289,598      37,903,514      703      616      667      887
  **Secondary care**                                                          1,417,061,030       443,333,624                         277,370,161     696,357,244     4,765    2,690    4,782    9,339
  Women                                                                       627,973,841         239,448,145                         119,681,362     268,844,335     4,352    2,725    4,866    8,447
  Men                                                                         789,087,188         203,885,480                         157,688,799     427,512,910     5,154    2,650    4,721    10,002
  **Pharmaceutical drug costs**                                               255,799,680         102,638,292                         62,354,493      90,806,895      860      623      1,075    1,218
  Women                                                                       124,231,968         56,257,489                          28,124,315      39,850,163      861      640      1,143    1,252
  Men                                                                         131,567,712         46,380,803                          34,230,178      50,956,732      859      603      1,025    1,192
  **Nursing costs**                                                           1,913,057,725       486,635,500                         319,986,457     1,106,435,768   6,433    2,953    5,517    14,838
  Women                                                                       1,181,279,919       347,648,931                         197,983,759     635,647,229     8,187    3,957    8,050    19,973
  Men                                                                         731,777,784         138,986,589                         122,002,705     470,788,491     4,780    1,806    3,652    11,015
  **Nursing home**                                                            850,952,193         211,354,084                         128,233,596     511,364,513     2,862    1,282    2,211    6,858
  Women                                                                       537,556,556         151,368,523                         82,046,366      304,141,667     3,726    1,723    3,336    9,556
  Men                                                                         313,395,637         59,985,561                          46,187,229      207,222,847     2,047    780      1,383    4,848
  **Nursing in own home**                                                     682,300,980         207,788,535                         123,110,097     351,402,347     2,294    1,261    2,123    4,713
  Women                                                                       421,328,648         149,028,783                         75,136,381      197,163,484     2,920    1,696    3,055    6,195
  Men                                                                         260,972,332         58,759,753                          47,973,716      154,238,863     1,705    764      1,436    3,609
  **Home nurse in own home**                                                  379,804,552         67,492,881                          68,642,764      243,668,907     1,277    410      1,183    3,268
  Women                                                                       222,394,715         47,251,626                          40,801,011      134,342,079     1,541    538      1,659    4,221
  Men                                                                         157,409,815         20,241,275                          27,841,759      109,326,781     1,028    263      833      2,558
  **Productivity loss**                                                       1,770,021,767       584,202,697                         360,442,062     825,377,008     5,952    3,545    6,214    11,069
  Women                                                                       550,569,259         245,373,990                         101,862,861     203,332,408     3,816    2,793    4,142    6,389
  Men                                                                         1,219,452,507       338,828,707                         258,579,201     622,044,600     7,965    4,403    7,741    14,553
  **Lost income**                                                             912,272,022         413,992,645                         184,680,345     313,599,033     3,068    2,512    3,184    4,206
  Women                                                                       317,068,466         190,042,378                         47,083,003      79,943,085      2,198    2,163    1,914    2,512
  Men                                                                         595,203,557         223,950,267                         137,597,342     233,655,947     3,888    2,910    4,119    5,467
  **Lost productivity in 2011 as a result of premature mortality**            32,477,477          3,584,403                           5,659,401       23,233,674      109      22       98       312
  Women                                                                       8,209,904           884,182                             1,901,945       5,423,777       57       10       77       170
  Men                                                                         24,267,574          2,700,221                           3,757,456       17,809,896      159      35       112      417
  **Lost productivity in 2011 as a result of premature deaths before 2011**   723,048,722         122,775,598                         144,419,340     455,853,784     2,431    745      2,490    6,113
  Women                                                                       187,784,170         35,195,124                          44,329,134      108,259,911     1,302    401      1,802    3,402
  Men                                                                         535,264,552         87,580,474                          100,090,205     347,593,872     3,496    1,138    2,996    8,132
  **Absence**                                                                 102,223,545         43,850,051                          25,682,976      32,690,518      344      266      443      438
  Women                                                                       37,506,720          19,252,307                          8,548,779       9,705,634       260      219      348      305
  Men                                                                         64,716,826          24,597,745                          17,134,197      22,984,884      423      320      513      538
  **Total additional costs**                                                  1,096,979,996       285,846,918                         193,084,112     618,048,966     3,689    1,734    3,329    8,288
  Women                                                                       499,242,465         152,580,215                         81,802,942      264,859,308     3,460    1,737    3,326    8,322
  Men                                                                         597,737,531         133,266,704                         111,281,170     353,189,657     3,904    1,732    3,331    8,263
  **Education, prevention, psychological assistance etc.**                    23,510,431          13,124,212                          4,710,462       5,675,757       79       80       81       76
  Women                                                                       11,433,432          7,005,481                           1,995,657       2,432,294       79       80       81       76
  Men                                                                         12,076,999          6,118,731                           2,714,805       3,243,462       79       80       81       76
  **SMBG and pumps**                                                          66,392,321          38,767,809                          13,283,599      14,340,912      223      235      229      192
  Women                                                                       32,467,058          20,693,596                          5,627,794       6,145,668       225      236      229      193
  Men                                                                         33,925,263          18,074,213                          7,655,806       8,195,243       222      235      229      192
  **Medical appliances**                                                      57,486,656          0                                   0               57,486,656      193      0        0        771
  Women                                                                       24,635,388          0                                   0               24,635,388      171      0        0        774
  Men                                                                         32,851,268          0                                   0               32,851,268      215      0        0        769
  **Patients' and informal care givers' time**                                345,542,010         183,886,084                         66,482,029      95,173,897      1,162    1,116    1,146    1,276
  Women                                                                       167,107,269         98,155,258                          28,166,096      40,785,915      1,158    1,117    1,145    1,282
  Men                                                                         178,434,741         85,730,825                          38,315,933      54,387,982      1,166    1,114    1,147    1,272
  **Depreciation**                                                            604,048,579         50,068,814                          108,608,022     445,371,743     2,031    304      1,873    5,973
  Women                                                                       263,599,318         26,725,880                          46,013,396      190,860,043     1,827    304      1,871    ½5,997
  Men                                                                         340,449,260         23,342,934                          62,594,626      254,511,701     2,224    303      1,874    5,955
  **Total for all cost items**                                                6,674,097,103       2,013,256,821                       1,255,306,273   3,405,534,010   22,443   12,216   21,643   45,670
  Women                                                                       3,096,916,097       1,104,543,408                       549,234,630     1,443,138,059   21,465   12,572   22,331   45,345
  Men                                                                         3,577,180,985       908,713,433                         706,071,649     1,962,395,903   23,365   11,809   21,137   45,912

C0, no complications; C1, minor complications; C2, major complications; SMBG, self‐monitoring of blood glucose.

John Wiley & Sons, Ltd

###### 

Diabetes attributable costs and attributable costs per person‐year for the diabetes population according to complication status and gender

  Cost item                                                           Total attributable cost (EUR)   Total attributable cost per person‐year (EUR)                                                           
  ------------------------------------------------------------------- ------------------------------- ----------------------------------------------- ------------- --------------- -------- ------- -------- --------
  **Healthcare costs**                                                731,520,509                     93,151,921                                      146,557,644   491,810,944     2,460    565     2,527    6,595
  Women                                                               307,076,026                     56,324,754                                      65,757,805    184,993,467     2,128    641     2,674    5,813
  Men                                                                 424,444,483                     36,827,167                                      80,799,839    306,817,477     2,772    479     2,419    7,178
  **Primary care**                                                    23,775,938                      8,071,606                                       4,630,869     11,073,463      80       49      80       149
  Women                                                               9,466,709                       3,358,214                                       2,032,360     4,076,136       66       38      83       128
  Men                                                                 14,309,229                      4,713,392                                       2,598,509     6,997,327       93       61      78       164
  **Secondary care**                                                  707,744,571                     85,080,316                                      141,926,775   480,737,481     2,380    516     2,447    6,447
  Women                                                               297,609,317                     52,966,541                                      63,725,445    180,917,331     2,063    603     2,591    5,685
  Men                                                                 410,135,255                     32,113,775                                      78,201,329    299,820,150     2,679    417     2,341    7,015
  **Pharmaceutical drug costs**                                       153,372,738                     51,151,437                                      43,493,499    58,727,802      516      310     750      788
  Women                                                               68,729,716                      25,830,792                                      18,958,706    23,940,218      476      294     771      752
  Men                                                                 84,643,022                      25,320,645                                      24,534,793    34,787,584      553      329     734      814
  **Nursing costs**                                                   851,426,972                     44,157,419                                      138,412,494   668,857,059     2,863    268     2,386    8,970
  Women                                                               530,191,480                     55,119,865                                      94,574,667    380,496,948     3,675    627     3,845    11,956
  Men                                                                 321,235,491                     ‐10,962,446                                     43,837,827    288,360,111     2,098    ‐142    1,312    6,746
  **Nursing home**                                                    271,179,210                     ‐22,733,872                                     29,375,665    264,537,417     912      ‐138    506      3,548
  Women                                                               214,979,658                     8,249,313                                       31,006,921    175,723,425     1,490    94      1,261    5,521
  Men                                                                 56,199,552                      ‐30,983,185                                     ‐1,631,255    88,813,992      367      ‐403    ‐49      2,078
  **Nursing in own home**                                             307,899,167                     47,914,035                                      59,025,923    200,959,210     1,035    291     1,018    2,695
  Women                                                               180,996,612                     39,487,891                                      36,882,579    104,626,142     1,254    449     1,500    3,287
  Men                                                                 126,902,555                     8,426,144                                       22,143,344    96,333,067      829      110     663      2,254
  **Home nurse in own home**                                          272,348,594                     18,977,256                                      50,010,906    203,360,433     916      115     862      2,727
  Women                                                               134,215,210                     7,382,661                                       26,685,167    100,147,381     930      84      1,085    3,147
  Men                                                                 138,133,384                     11,594,594                                      23,325,738    103,213,051     902      151     698      2,415
  **Productivity loss**                                               1,770,021,767                   584,202,697                                     360,442,062   825,377,008     5,952    3,545   6,214    11,069
  Women                                                               550,569,259                     245,373,990                                     101,862,861   203,332,408     3,816    2,793   4,142    6,389
  Men                                                                 1,219,452,507                   338,828,707                                     258,579,201   622,044,600     7,965    4,403   7,741    14,553
  **Lost income**                                                     912,272,022                     413,992,645                                     184,680,345   313,599,033     3,068    2,512   3,184    4,206
  Women                                                               317,068,466                     190,042,378                                     47,083,003    79,943,085      2,198    2,163   1,914    2,512
  Men                                                                 595,203,557                     223,950,267                                     137,597,342   233,655,947     3,888    2,910   4,119    5,467
  **Lost productivity in 2011 due to premature mortality**            32,477,477                      3,584,403                                       5,659,401     23,233,674      109      22      98       312
  Women                                                               8,209,904                       884,182                                         1,901,945     5,423,777       57       10      77       170
  Men                                                                 24,267,574                      2,700,221                                       3,757,456     17,809,896      159      35      112      417
  **Lost productivity in 2011 due to premature deaths before 2011**   723,048,722                     122,775,598                                     144,419,340   455,853,784     2,431    745     2,490    6,113
  Women                                                               187,784,170                     35,195,124                                      44,329,134    108,259,911     1,302    401     1,802    3,402
  Men                                                                 535,264,552                     87,580,474                                      100,090,205   347,593,872     3,496    1,138   2,996    8,132
  **Absence**                                                         102,223,545                     43,850,051                                      25,682,976    32,690,518      344      266     443      438
  Women                                                               37,506,720                      19,252,307                                      8,548,779     9,705,634       260      219     348      305
  Men                                                                 64,716,826                      24,597,745                                      17,134,197    22,984,884      423      320     513      538
  **Total additional costs**                                          760,778,770                     257,979,629                                     132,635,083   370,164,058     2,558    1,565   2,287    4,964
  Women                                                               352,528,414                     137,705,130                                     56,192,816    158,630,468     2,443    1,567   2,285    4,984
  Men                                                                 408,250,356                     120,274,499                                     76,442,267    211,533,590     2,667    1,563   2,288    4,949
  **Education, prevention, psychological assistance etc.**            23,510,431                      13,124,212                                      4,710,462     5,675,757       79       80      81       76
  Women                                                               11,433,432                      7,005,481                                       1,995,657     2,432,294       79       80      81       76
  Men                                                                 12,076,999                      6,118,731                                       2,714,805     3,243,462       79       80      81       76
  **SMBG and pumps**                                                  66,392,321                      38,767,809                                      13,283,599    14,340,912      223      235     229      192
  Women                                                               32,467,058                      20,693,596                                      5,627,794     6,145,668       225      236     229      193
  Men                                                                 33,925,263                      18,074,213                                      7,655,806     8,195,243       222      235     229      192
  **Medical appliances**                                              57,486,656                      0                                               0             57,486,656      193      0       0        771
  Women                                                               24,635,388                      0                                               0             24,635,388      171      0       0        774
  Men                                                                 32,851,268                      0                                               0             32,851,268      215      0       0        769
  **Patients' and informal care givers' time**                        345,542,010                     183,886,084                                     66,482,029    95,173,897      1,162    1,116   1,146    1,276
  Women                                                               167,107,269                     98,155,258                                      28,166,096    40,785,915      1,158    1,117   1,145    1,282
  Men                                                                 178,434,741                     85,730,825                                      38,315,933    54,387,982      1,166    1,114   1,147    1,272
  **Depreciation**                                                    267,847,352                     22,201,524                                      48,158,993    197,486,835     901      135     830      2,648
  Women                                                               116,885,267                     11,850,795                                      20,403,270    84,631,202      810      135     830      2,659
  Men                                                                 150,962,085                     10,350,729                                      27,755,723    112,855,634     986      135     831      2,640
  **Total for all cost items**                                        4,267,120,755                   1,030,643,103                                   821,540,781   2,414,936,871   14,349   6,254   14,164   32,386
  Women                                                               1,809,094,895                   520,354,532                                     337,346,855   951,393,509     12,539   5,923   13,716   29,894
  Men                                                                 2,458,025,860                   510,288,571                                     484,193,927   1,463,543,362   16,055   6,631   14,495   34,241

C0, no complications; C1, minor complications; C2, major complications; SMBG, self‐monitoring of blood glucose.

John Wiley & Sons, Ltd

###### 

Total person‐years for the entire diabetes population according to complication status and gender

  Person years   All       No complications   Minor complications   Major complications
  -------------- --------- ------------------ --------------------- ---------------------
  Total          297,378   164,809            58,000                74,568
  Women          144,281   87,860             24,595                31,826
  Men            153,097   76,950             33,405                42,742

John Wiley & Sons, Ltd

Healthcare {#dme12965-sec-0011}
----------

Total healthcare costs were estimated to be 1.64 billion Euro, corresponding to 5509 EUR per person‐year. On average, a patient with diabetes consumed approximately twice the healthcare resources compared with a diabetes‐free person (1.2, 1.8 and 2.8 times the healthcare resource use of a diabetes‐free person for patients with no, minor or major complications, respectively) with higher gradients found among younger patients as compared with the elderly, among male patients as compared with female patients, and for secondary care as compared with primary care. A patient going from no complications to minor or major complications incurred increased healthcare costs of 1782 and 7534 EUR per person‐year, respectively, even after controlling for potential confounders (Table S6).

The total attributable healthcare costs of diabetes were estimated to be 732 million EUR, divided between the no complication, minor complication and major complication groups as follows: 93, 147 and 492 million EUR, respectively. The greatest absolute cost burden was observed in the age group of 60--74 years, mainly because of the sheer volume of patients in these age groups.

Average attributable costs per person‐year for healthcare were 2460 EUR (2,128 EUR for women and 2,772 EUR for men). The costs for patients with minor complications were 4.5 times higher and for patients with major complications 12 times higher than for patients without complications. Patients with major complications, representing 25% of all patients, consumed almost 50% of total healthcare resources. Differences in attributable healthcare costs between a patient with no complications and a patient with minor or major complications of 1617 and 7388 EUR per person‐year, respectively, were found, after controlling for potential confounders (Table S7).

Observed patterns in healthcare resource consumption are shown in Fig. [1](#dme12965-fig-0001){ref-type="fig"} and may be summarized as follows: 1) gradients between complication status groups were especially marked for secondary care, where the largest costs also lay; 2) men consumed more resources in all secondary care services than women, whereas the opposite was true for primary care; and 3) attributable cost per person‐year decreased with age, mainly as a result of the diabetes‐free population experiencing an increase in cost with age.

![Total cost of secondary care for the diabetes‐free population (DKnoDM) and patients with diabetes (DM) by complication state (C0: no, C1: minor and C2: major) for (a) women and (b) men.](DME-33-877-g001){#dme12965-fig-0001}

Pharmaceutical drugs {#dme12965-sec-0012}
--------------------

Pharmaceutical drug consumption amounted to 256 million EUR in 2011, corresponding to 860 EUR per person. Differences in the costs between no complications and minor and major complications, respectively, were 257 and 329 EUR per year, after controlling for potential confounders (Table S8). The pharmaceutical drug consumption of patients with diabetes was 2.5 times higher than that of the diabetes‐free population: 153 million Euro were found to be attributable to diabetes. Attributable costs per person‐year were 516 EUR (476 EUR for women and 553 EUR for men), and were 310, 750 and 788 EUR per person‐year for the no complication, minor complication and major complication groups, respectively. This shows a significant increase in pharmaceutical drug costs when patients progressed from uncomplicated diabetes to minor complications, whereas later progression to major complications did not impose a marked increase. For women, the increase from minor to major complications was 2% and for men 10%. The higher attributable costs among men were the result of differences in pharmaceutical drug consumption between genders in the control group, whereas consumption was approximately equal for each gender among patients with diabetes.

Attributable costs were highest among the young, and declined with age (Fig. [2](#dme12965-fig-0002){ref-type="fig"}). This pattern is mainly the result of patients with diabetes having more or less the same pharmaceutical drug consumption across age groups, whereas there was increasing consumption with age among the control subjects.

![Diabetes‐attributable cost for pharmaceuticals by age, gender and complication status (C0: no, C1: minor and C2: major).](DME-33-877-g002){#dme12965-fig-0002}

Nursing {#dme12965-sec-0013}
-------

Costs for nursing for patients with diabetes in 2011 amounted to 1.91 billion EUR, corresponding to 6,433 EUR per person. Total attributable nursing costs amounted to 851 million corresponding to 2,863 EUR per person‐year (3,675 EUR for women and 2,098 EUR for men). When the attributable costs were divided between the no complication, minor complication and major complication groups, the costs were 268, 2,386 and 8,970 EUR, respectively, per patient. Attributable costs per patient hence increased 33‐fold when patients progressed from uncomplicated diabetes to diabetes with major complications**.**

The probability of living in a nursing home for patients with diabetes was 45% greater compared with the matched diabetes‐free population. For men (in particular those aged ≥ 75 years) negative attributable costs were evidenced, reflecting that men in these older age groups, who have no complications, use fewer nursing resources than aged‐matched men in the diabetes‐free population. Patients with diabetes received on average 50% more home nursing visits than the matched diabetes‐free population. The difference in total costs for home nursing between patients with no complications and those with minor and major complications were estimated to be 299 and 722 EUR per year, respectively, after controlling for potential confounders (Table S9).

Productivity {#dme12965-sec-0014}
------------

In total, the productivity loss amounted to 1.77 billion EUR, assuming patients with diabetes of working age earned the same income as the diabetes‐free population of the same age, gender and education level, died at the same age and had not experienced any excess days of absence attributable to disease.

Patients with diabetes on average received a lower annual gross income than matched control subjects after controlling for education level. This reflected that a higher percentage of control subjects had jobs requiring high‐level skills, e.g. almost twice as many control subjects held jobs in managerial positions, whereas patients with diabetes had a 22% higher unemployment rate and more than twice as many had retired early (12% compared with 5.4%). Differences in income level increased with education level and complication status group, with a maximum annual difference among patients with major complications belonging to the highest education level group of 25,229 EUR for men and 24,104 EUR for women in the age group 55--59 years. The annual difference in mean gross income according to age in four education level groups is shown for the no complications group, with men and women separately in Fig. [3](#dme12965-fig-0003){ref-type="fig"}.

![Annual difference in mean gross income according to age and education level for (a) women and (b) men with no diabetes complications.](DME-33-877-g003){#dme12965-fig-0003}

The total attributable difference in annual gross income was 912 million EUR. The main share (46%) of the total productivity loss was attributable to productivity losses among patients with no complications, because of the volume of people of working age. Lost productivity in 2011 as a result of premature death from diabetes was 32.4 million EUR calculated from 1,567 premature deaths corresponding to 52% of the total number of deaths among patients with diabetes of working age and to 1% of the total diabetes population in the working age group. Production foregone in 2011 as a result of premature deaths from diabetes encountered before 2011 (with production foregone as a result of the diabetes‐attributable deaths until the age of 69 years used as proxy estimate) was estimated to be 723 million EUR, and excess days of absence from work were estimated to be 102 million EUR in 2011.

Additional costs {#dme12965-sec-0015}
----------------

Additional costs attributable to diabetes were estimated to be 761 million EUR corresponding to 2,558 EUR per person‐year.

Total attributable costs {#dme12965-sec-0016}
------------------------

The total costs of diabetes in Denmark in 2011 were estimated to be 6.67 billion EUR (22,443 EUR per person‐year), of which 4.27 billion EUR (14,349 EUR per person‐year) were attributable to diabetes. The relative distribution between cost components is shown in Fig. [4](#dme12965-fig-0004){ref-type="fig"}, and the absolute distribution is shown in the Figure S1.

![Relative distribution of the components of diabetes‐attributable costs.](DME-33-877-g004){#dme12965-fig-0004}

The total diabetes‐attributable costs were divided between the no complication, minor complication and major complication groups as follows: 6,254, 14,164 and 32,386 EUR per person‐year, respectively (Fig. [5](#dme12965-fig-0005){ref-type="fig"}).

![Diabetes attributable costs according to complication status (C0: no complications; C1: minor complications; C2: major complications) and gender.](DME-33-877-g005){#dme12965-fig-0005}

The relative distribution of total attributable costs according to complication status and number of person‐years showed that 25% of patients with diabetes consumed nearly 60% of attributable costs (Fig. [6](#dme12965-fig-0006){ref-type="fig"}).

![Relative distribution of person years (a) and diabetes attributable costs (b) according to complication status (C0: no complications; C1: minor complications; C2: major complications).](DME-33-877-g006){#dme12965-fig-0006}

Discussion {#dme12965-sec-0017}
==========

We found that patients with diabetes consumed approximately twice the healthcare resources consumed by people without diabetes. This is less than that documented in earlier studies [20](#dme12965-bib-0020){ref-type="ref"}, indicating that the population with diabetes is becoming less resource‐demanding in the healthcare sector per person‐year, probably as a result of improvements in prognosis [21](#dme12965-bib-0021){ref-type="ref"}, [22](#dme12965-bib-0022){ref-type="ref"}. Compared with the diabetes‐free population, patients with diabetes incurred their resource use earlier in life, while later in life they required more specialized care. When patients with diabetes developed complications, the healthcare and nursing costs increased markedly. Men in particular used fewer healthcare services before complications, whereas later they were more likely than women to progress to major complications with a need for specialized care. We show a marked increase in healthcare costs with increasing complications, even after controlling for relevant confounders. These findings correspond to those of other studies, which document major costs related to diabetes complications [23](#dme12965-bib-0023){ref-type="ref"}, [24](#dme12965-bib-0024){ref-type="ref"}. This highlights the cost‐saving potential of preventing complications among patients with diabetes and hence the importance of secondary prevention. Acknowledging that more people are living for longer with diabetes because of prognosis improvements, and that these epidemiological trends cannot be turned around in the short or medium term [21](#dme12965-bib-0021){ref-type="ref"}, [22](#dme12965-bib-0022){ref-type="ref"}, the importance of prevention of expensive complications is highlighted. We found that patients' morbidity characteristics were the most important predictors of diabetes‐attributable costs. Interestingly, however, the multivariate analysis, showed significant cost differences according to region of residence, education level and year of death. This latter finding indicates that the high attributable costs for younger patients with diabetes might, to some degree, be attributable to death *per se*, irrespective of the cause of death. This methodological issue should be further investigated. Likewise, underlying associations between patients' characteristics and their morbidity patterns are important to investigate further in order to target prevention and treatment efforts. These issues will be dealt with in future work.

Regarding pharmaceutical drug consumption, the greatest increase in costs was found to be between patients with no complications and those with minor complications. Clinically, this might be explained by patients with minor complications being heavily medicated to prevent progression to major complications. Gender differences point to women being more proactive in receiving pharmaceutical drugs earlier in their diabetes (with fewer complications) than men. Nursing costs were found to be concentrated among patients with major complications, corresponding to recent structural changes in Denmark with respect to nursing services being offered. Patients with diabetes were more costly than the diabetes‐free population, in particular with respect to visits by a home nurse. Results clearly show evidence for different labour market patterns among patients with diabetes compared with the control subjects, and increasing loss in productivity among patients with diabetes was seen with an increase in complication levels. When controlling for education level, it was evident that the main extent of the income disparities could not be accounted for by the fact that the diabetes incidence was higher among people with lower income. We therefore expect the difference to be attributable to the influence of the ability of the person with diabetes to work, thus resulting in a lower annual income. Even though diabetes mainly affects older people in society, looking at patient volume, we show major costs to society as well as to the individual in relation to productivity.

The exclusion of patients registered in the Danish National Diabetes Register solely because of frequent blood glucose measurements (63,647 person‐years) [12](#dme12965-bib-0012){ref-type="ref"} resulted in a reduction in patients with no complications. Total attributable costs were decreased by 9% (to 3.9 billion EUR), but attributable cost per person‐year increased. We conclude therefore that estimates for patients with no complications might be underestimated.

The chosen approach with a 1‐year time window has its limitations, but it allowed a descriptive analysis of the population in this year [25](#dme12965-bib-0025){ref-type="ref"}. It would be advantageous to include more years to facilitate analysis of trends over time. Our data did not allow a distinction between Type 1 and Type 2 diabetes, which would be advantageous taking the different aetiology into consideration. Our findings across age groups indicate high attributable costs among children and teenagers, reflecting that the diabetes‐free population in these age groups consumes markedly less healthcare, nursing services and pharmaceutical drugs.

Categorizing patients according to their development of complications; i.e. no complications, minor complications and major complications, is a novel method within this field. We aimed to contribute to this field with an easily understandable outline of the cost pattern for a very complex disease, providing decision‐makers with the necessary guidance for future investments in diabetes.

The presented cost distributions by component and by complication status are presumably not only valid in a Danish setting but could be transferred to other countries and chronic diseases.

Based on all available data in Danish national health registers for all patients with diabetes in 2011, the costs attributable to diabetes were estimated to be at least 4.27 billion EUR, corresponding to 14,349 EUR per person‐year. We show a steep increase in attributable costs for patients with major complications compared with patients without complications across all cost components, also when potential confounders are controlled for. Our results underline the universal message of cost increases with increased complications, providing an economic rationale for secondary prevention.

Evidence of cost distributions within diabetes can guide future efforts in specific sectors, or targeted patient groups, based on expected cost savings.
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